{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T05:03:29Z","timestamp":1696914209612},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T00:00:00Z","timestamp":1112140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Pharma Physio"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>1.\u2002Glyceryl trinitrate (GTN) is frequently infused intravenously as a component of the management of acute coronary syndromes (ACS). Abrupt cessation of GTN infusion after periods of more than 24\u00a0h administration often induces rebound vasoconstriction reflecting \u2018pseudotolerance\u2019; this is also the basis of the \u2018zero hour phenomenon\u2019 during chronic nitrate therapy. The efficacy of oral nitrate regimens to prevent vasoconstriction following cessation of intravenous GTN has not been previously examined. Therefore, we investigated the effects of transition from intravenous GTN to oral isosorbide dinitrate (ISDN) on a parameter of apparent arterial stiffness in patients with ACS.<\/jats:p><jats:p>2.\u2002The effects of GTN infusion at 5\u00a0\u00b5g\/min on augmentation index (AIx) were quantified in patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a010) with stable angina pectoris in order to establish the magnitude of effect on apparent arterial stiffness.<\/jats:p><jats:p>3.\u2002This infusion rate of GTN reduced AIx from 23\u00a0\u00b1\u00a010% (SD) to 3\u00a0\u00b1\u00a014% (SD) (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00.01). The effect of transition from GTN infusion of greater than 24\u00a0h duration to ISDN (10\u00a0mg tds) were examined in patients (<jats:italic>n<\/jats:italic>\u00a0=\u00a016) with ACS (unstable angina\/non\u2010Q\u2010wave myocardial infarction). No patient developed recurrent angina during the 24\u00a0h following cessation of GTN infusion. The level of AIx was 8\u00a0\u00b1\u00a04% (SD) prior to GTN cessation and fell to 5\u00a0\u00b1\u00a06% (SD) on ISDN (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.05).<\/jats:p><jats:p>4.\u2002Thus, in patients treated for ACS, transition from intravenous GTN to low dose oral ISDN is associated with an incremental vasodilatation and no evidence of \u2018rebound\u2019 ischaemia.<\/jats:p>","DOI":"10.1111\/j.1440-1681.2005.04182.x","type":"journal-article","created":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T12:37:27Z","timestamp":1112186247000},"page":"269-272","source":"Crossref","is-referenced-by-count":5,"title":["WITHDRAWAL OF INTRAVENOUS GLYCERYL TRINITRATE: ABSENCE OF REBOUND PHENOMENA WITH TRANSITION TO ORAL ISOSORBIDE DINITRATE"],"prefix":"10.1111","volume":"32","author":[{"given":"Elizabeth A","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah M","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,30]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.suppl_4.IV-2"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.77.3.375"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.23.2810"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.78.4.906"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90595-P"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00053031"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.10.2855"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)02268-8"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1987.tb136273.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00268-4"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00984-0"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajim.4700150610"},{"key":"e_1_2_6_14_2","first-page":"136","article-title":"Withdrawal symptoms in workers exposed to nitroglycerine","volume":"25","author":"Lund RP","year":"1968","journal-title":"Br. J. Ind. Med."},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a059909"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(89)90216-7"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/oxfordjournals.eurheartj.a059425","article-title":"Intermittent transdermal nitroglycerin monotherapy in stable exercise\u2010induced angina: A comparison with a continuous schedule","volume":"10","author":"Ferratini M","year":"1989","journal-title":"Eur. Heart J."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)00416-N"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(85)91126-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.68.6.1247"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.73.1.138"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/14.2.160"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.37.6.1434"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/hy1201.098767"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198606123142404"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.15.4.339"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(85)91123-3"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162303"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a059669"}],"container-title":["Clinical and Experimental Pharmacology and Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1681.2005.04182.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1681.2005.04182.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T19:34:46Z","timestamp":1696880086000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1681.2005.04182.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,30]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1111\/j.1440-1681.2005.04182.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1681.2005.04182.x","archive":["Portico"],"relation":{},"ISSN":["0305-1870","1440-1681"],"issn-type":[{"value":"0305-1870","type":"print"},{"value":"1440-1681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,30]]}}}